The role of HBsAg levels in the current management of chronic HBV infection

RDF 

 
This item is provided by the institution :
Hellenic Gastroenterologiki Company
Repository :
Annals of Gastroenterology
see item page
in the web site of the repository *
share



Semantic enrichment/homogenization by EKT
The role of HBsAg levels in the current management of chronic HBV infection (EN)

Höner zu Siederdissen, Christoph; Dept of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
Cornberg, Markus; Dept of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

Chronic hepatitis B virus (HBV) infection can result in liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). However, the natural course of the disease is highly dynamic and not every patient requires therapy. The challenges for optimal management are who to treat, which therapeutic regimen to use, and when to begin or stop treatment. Constant monitoring is mandatory to predict the natural course and guide treatment decisions. Surrogate markers for baseline and on treatment decisions are needed. Besides HBV DNA, hepatitis B surface antigen levels also proved to be useful to help judge the natural course and guide treatment. High levels of HBsAg are suggestive of low fibrosis and immune tolerance in hepatitis B e antigen (HBeAg) positive patients; whereas low levels of HBsAg indicate a lower risk for HCC and inactive carrier state in HBeAg negative patients. Data also support the possible use of HBsAg levels as an on-treatment response marker. So far, the best evidence exists for treatment with interferon (IFN)-α where lack of HBsAg decline after 12 weeks is associated with non-response. Thus, stopping rules after 12 weeks therapy could be established for HBeAg positive as well as for HBeAg negative patients. However, the positive predictive value for achieving sustained response is still vague. The value of HBsAg monitoring is less clear during treatment with nucleos(t)ide analogues (NA) but it can be a useful marker for new concepts such as stopping NA or add-on IFN strategies. Currently, several studies are underway to validate HBsAg in these settings.Keywords Chronic hepatitis B, hepatitis B surface antigen, interferon α, nucleos(t)ide analoguesAnn Gastroenterol 2014; 27 (2): 105-112 (EN)

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Gastroenterologiki Company (EN)

2014-03-27


Annals of Gastroenterology (EN)

Annals of Gastroenterology; Volume 27, No 2 (2014); 105 (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)